Posted by Michael Wonder on 01 Jun 2021
Janssen announces U.S. FDA breakthrough therapy designation granted for teclistamab for the treatment of relapsed or refractory multiple myeloma
1 June 2021 - U.S. milestone follows EMA PRIME designation for this BCMA bi-specific antibody for the treatment of relapsed or refractory multiple myeloma.
Janssen announced today that the U.S. FDA has granted breakthrough therapy designation for teclistamab in the treatment of relapsed or refractory multiple myeloma.
